Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.71 USD | -0.33% | +0.86% | +4.45% |
Jul. 08 | Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births | RE |
Jul. 08 | UBS Downgrades GSK to Neutral From Buy | MT |
Chart calendar GSK plc
Upcoming events on GSK plc
Past events on GSK plc
2024-06-17 08:00 am | Analyst Meeting - Getting Ahead of Cancer |
2024-06-05 | BNP Paribas Exane CEO Conference |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #8627 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #LBA3512 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #8017 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #7530 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #TPS5627 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e19523 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #TPS6125 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e19532 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e19524 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e19507 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e19503 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #7559 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #e23110 |
2024-05-30 | American Society of Clinical Oncology Meeting - MV. Mateos |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #7503 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #7543 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #5606 |
2024-05-30 | American Society of Clinical Oncology Meeting - Abstract No - #5607 |
Past dividends on GSK plc
2024-05-15 | Interim Payment 0.15 GBP |
2024-02-21 | Final Payment 0.16 GBP |
2023-11-15 | Interim Payment 0.14 GBP |
2023-08-16 | Interim Payment 0.14 GBP |
2023-05-17 | Interim Payment 0.14 GBP |
2023-02-22 | Final Payment 0.1375 GBP |
2022-11-16 | Interim Payment 0.1375 GBP |
2022-08-17 | Interim Payment 0.1625 GBP |
2022-07-17 | 0 GBP |
2022-05-18 | Interim Payment 0.14 GBP |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million GBP | Released Forecast Spread | 33 754 33 382 1.11% | 34 099 34 076 0.07% | 34 114 34 029 0.25% | 29 324 29 105 0.75% | 30 328 29 850 1.6% | 31 593 |
EBITDA Million GBP | Released Forecast Spread | 11 968 11 155 7.28% | 9 530 10 575 -9.88% | 11 330 10 048 12.76% | 10 449 9 257 12.88% | 11 635 10 203 14.04% | 10 589 |
EBIT Million GBP | Released Forecast Spread | 8 972 9 182 -2.29% | 8 906 8 955 -0.55% | 8 806 8 717 1.02% | 8 151 7 952 2.5% | 8 786 8 780 0.07% | 9 162 |
Earnings before Tax (EBT) Million GBP | Released Forecast Spread | 6 221 5 926 4.97% | 6 968 6 763 3.02% | 5 442 5 794 -6.07% | 5 628 5 548 1.45% | 6 064 7 498 -19.12% | 7 359 |
Net income Million GBP | Released Forecast Spread | 4 645 4 026 15.38% | 5 749 4 894 17.46% | 4 385 3 990 9.91% | 14 956 6 238 139.74% | 4 928 5 481 -10.09% | 5 407 |
EPS GBP | Released Forecast Spread | 1,16 1,06 9.69% | 1,43 1,21 17.91% | 1,08 1,02 6.28% | 3,66 1,66 120.52% | 1,22 1,38 -11.61% | 1,31 |
Announcement Date | 05/02/20 | 03/02/21 | 09/02/22 | 01/02/23 | 31/01/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million GBP | Released Forecast Spread | 9 780 9 145 6.94% | 6 929 6 906 0.33% | 7 829 7 214 8.52% | 7 376 7 101 3.88% | 6 951 6 580 5.64% | 7 178 6 795 5.63% | 8 147 7 727 5.43% | 8 052 7 621 5.65% | 7 363 7 060 4.3% | 7 520 | 8 517 | 8 155 | 7 590 | 7 865 |
EBITDA Million GBP | Released Forecast Spread | 3 317 2 850 16.4% | 2 639 2 138 23.45% | 3 561 2 704 31.68% | 1 602 1 855 -13.63% | 2 732 2 418 12.97% | 2 622 2 506 4.64% | 3 351 3 072 9.09% | 2 930 2 094 39.93% | 2 992 2 406 24.36% | 2 510 | 3 117 | 1 784 | ||
EBIT Million GBP | Released Forecast Spread | 2 613 2 291 14.06% | 2 008 1 740 15.4% | 2 605 2 264 15.08% | 1 595 1 509 5.7% | 2 092 1 930 8.42% | 2 170 1 999 8.56% | 2 772 2 570 7.88% | 1 752 1 836 -4.58% | 2 443 2 099 16.38% | 2 203 | 2 791 | 1 723 | 2 408 | 2 487 |
Earnings before Tax (EBT) Million GBP | Released Forecast Spread | 2 598 2 268 14.55% | 896 1 243 -27.89% | 1 012 1 860 -45.59% | 1 626 946 71.97% | 1 907 1 529 24.72% | 1 987 1 500 32.51% | 1 791 2 225 -19.51% | 379 1 361 -72.15% | 1 355 1 696 -20.11% | 1 818 | 2 462 | 1 241 | ||
Net income Million GBP | Released Forecast Spread | 1 802 1 674 7.66% | 975 802 21.54% | 10 315 1 356 660.76% | 1 495 1 151 29.9% | 1 490 1 179 26.41% | 1 624 1 213 33.86% | 1 464 1 739 -15.79% | 350 834 -58.04% | 1 046 1 297 -19.32% | 1 378 | 1 881 | 1 163 | ||
EPS GBP | Released Forecast Spread | 0,45 0,41 8.83% | 0,21 0,21 -3.22% | 2,52 0,34 640.73% | 0,37 0,19 95.19% | 0,37 0,29 27.52% | 0,40 0,30 35.52% | 0,36 0,43 -15.26% | 0,09 0,20 -58.02% | 0,25 0,31 -19.17% | 0,33 | 0,46 | 0,21 | ||
Announcement Date | 27/04/22 | 27/07/22 | 02/11/22 | 01/02/23 | 26/04/23 | 26/07/23 | 01/11/23 | 31/01/24 | 01/05/24 | - | - | - | - | - |
2024-07-10 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2025 Earnings Release |
2024-07-15 | CAMURUS AB: Q2 2024 Earnings Release |
2024-07-16 | GLAND PHARMA LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-17 06:45 am | JOHNSON & JOHNSON: Q2 2024 Earnings Release |
2024-07-17 | JUBILANT PHARMOVA LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-18 01:00 am | NOVARTIS AG: Q2 2024 Earnings Release |
2024-07-18 | TEYI PHARMACEUTICAL GROUP CO.,LTD: Q2 2024 Earnings Release |
2024-07-21 | GLAXOSMITHKLINE PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-21 | ALMIRALL, S.A.: Q2 2024 Earnings Release |
2024-07-22 | TORRENT PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
Past sector events for GSK plc
2024-07-03 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2024 Earnings Release (Projected) |
2024-06-21 11:28 am | DEVA HOLDING: Q1 2024 Earnings Release |
2024-06-13 05:21 pm | EIS ECZACIBASI ILAÇ, SINAI VE FINANSAL YATIRIMLAR SANAYI VE TICARET: Q1 2024 Earnings Release |
2024-06-11 01:30 am | BORA PHARMACEUTICALS CO., LTD.: June 2024 Sales and Revenue Release |
2024-06-07 06:33 am | SCINOPHARM TAIWAN, LTD.: May 2024 Sales and Revenue Release |
2024-06-07 05:17 am | LOTUS PHARMACEUTICAL CO., LTD.: May 2024 Sales and Revenue Release |
2024-05-30 08:08 am | SUVEN PHARMACEUTICALS LIMITED: Q4 2024 Earnings Release |
2024-05-30 07:00 am | ROIVANT SCIENCES LTD.: Q4 2023 Earnings Release |
2024-05-30 02:24 am | MARKSANS PHARMA LIMITED: Q4 2024 Earnings Release |
2024-05-29 08:00 am | FDC LIMITED: Q4 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- GSK Stock
- GSK Stock
- Calendar GSK plc